TY - CHAP M1 - Book, Section TI - Hematologic Manifestations of Human Immunodeficiency Virus and the Acquired Immunodeficiency Syndrome A1 - Menon, Manoj P. A1 - Harrington, Robert D. A1 - Broudy, Virginia C. A2 - Kaushansky, Kenneth A2 - Prchal, Josef T. A2 - Burns, Linda J. A2 - Lichtman, Marshall A. A2 - Levi, Marcel A2 - Linch, David C. Y1 - 2021 N1 - T2 - Williams Hematology, 10e AB - SUMMARYThe prevalence of HIV in the United States continues to rise as a result of the combined effects of a declining HIV death rate and a sustained rate of new infections. Furthermore, HIV-infected patients on antiretroviral therapy can expect to live nearly almost as long as uninfected persons (within 5 years) providing ample time for individuals to develop AIDS-associated and non–AIDS-associated hematologic and oncologic conditions. HIV-infected individuals remain at increased risk of AIDS-defining malignancies such as Kaposi sarcoma, aggressive non-Hodgkin lymphoma, primary CNS lymphoma, and invasive cervical cancer and several non–AIDS-defining malignancies, including Hodgkin lymphoma, as well as anemia and thrombocytopenia. When individuals present with any of these hematologic or malignant illnesses, it should be the standard of care to obtain HIV testing to provide optimal treatment for both the presenting illness and the HIV. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1178758221 ER -